Loading market dashboard
Bio-Rad Laboratories, Inc.
BIOHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
KUALA LUMPUR, MALAYSIA, June 04, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; the “Company”) today announced that it entered into a Business Combination Agreement (“BCA”) with Future NRG Sdn. Bhd. (“Future NRG”) in an all stock share exchange transaction. Future NRG is a Malaysia-based technology integrator and project developer operating at the forefront of innovative and sustainable medical waste management, for healthcare waste generators including clinics, dental practices, veterinary clinics, dialysis centers, laboratories, and factories, offering advanced waste-to-energy and waste-to-resource projects using advanced, market-proven clean technology. Upon completion of the share exchange, which is subject to approval by BGMS and Future NRG's shareholders, the combined company is expected to continue operating under the name Bio Green Med Solution, Inc. and continue trading on the Nasdaq Capital Market under the ticker symbol “BGMS”.
BIO-key's RedChip Future Tech Investor Conference Presentation to Webcast Wed. June 10 at 3pm ET URL: https://www.redchip.com/webinar/redchip/89763628854.
Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Kelowna, British Columbia - June 3 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that it is attending the BIO International Convention (“BIO”) from June 22-25 in San Diego, CA . Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development (“BD”) program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference. “We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is a potential target for therapy and prevention of cancer Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs) PONTE VEDRA, Fla., June 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced its participation in the BIO International Convention 2026 Partnering Event (BIO 2026) taking place June 22–25, 2026, at the San Diego Convention Center.
BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit Union via Strategic IT Solutions Partnership with Provider BlueAlly
BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit Union via Strategic IT Solutions Partnership with Provider BlueAlly
On May 28, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 4.2% today, closing at a price of $318.22. The stock has shown significant performance over the last
Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories (BIO), putting fresh activist pressure on a life-science tools suppli
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA) in a joint briefing held on May 14, 2026. The session was Valion Bio's second engagement with senior Department of War officials, following the Company's April 28, 2026, Pentagon briefing on Entolimod.
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
HOLMDEL, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (OTC Markets: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its first quarter (Q1'26) results and first half of 2026 (1H'26) outlook.
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced first quarter financial results and provided a business update.
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity Bioworks Conference Call to be Held Today at 1:30 PM PT / 4:30 PM ET SAN ANTONIO , May 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, today reported financial results for the three months ended March 31, 2026 — the company's first full reporting quarter under its new corporate identity — and provided a business update on the continued advancement of its Entolimod platform, ongoing engagement with U.S. government agencies, and continued integration of wholly owned manufacturing subsidiary Velocity Bioworks. First Quarter 2026 Highlights and Subsequent Events Completed corporate transformation, including the change of the company's legal name from Tivic Health Systems, Inc. to Valion Bio, Inc. and the change of the company's Nasdaq listing symbol from TIVC to VBIO, consolidating the company's identity as a focused clinical-stage immunotherapeutics platform.
HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC that the trading of its common stock will be suspended on Nasdaq effective with markets' close today, Tuesday, May 12, 2026.
HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host its Q1'26 investor call and webcast on Monday, May 18th at 10 a.m.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Format: Fireside chat and one-on-one investor meetings Participants: Roop K. Lakkaraju, Chief Financial Officer Date and Time: Tuesday, May 19, 2026, at 8:30 AM Eastern Time; a live webc.
Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure Has Demonstrated Efficacy SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) (formerly Tivic Health Systems, Inc.), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health. Under the agreement — valued at up to $7 million — NIAID will fully fund the in vivo studies required to support the Company's Biologics License Application (BLA) for Entolimod™ under the FDA's Animal Rule pathway, with the agency further committed to co-navigate the FDA submission process alongside Valion Bio upon favorable study outcomes.
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
On May 01, 2026, Bio-Rad Laboratories Inc (BIO) shares fell 8.4% today, bringing the current price to $256.55. This decline is significant in the context of the
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $1.89 per share, missing the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.54 per share a year ago.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite external headwinds including challenging academic end markets and conflict escalation in the.
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a late-stage immunotherapeutics company, today announced that it briefed senior officials at the U.S. Department of War on Entolimod™ for acute radiation syndrome. The briefing, facilitated by American Defense International (ADI), was presented to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs and his team at the Pentagon.
HOLMDEL, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced that it has approved a 1-for-10 reverse stock split that will become effective with the commencement of trading on April 30, 2026.
Boston Trust Walden Corp decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,838 shares of the medical research company's stock after selling 5,610 shares during the period. Boston
HOLMDEL, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced today that it has received a notification letter from The Nasdaq Stock Market, LLC informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company's failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on Thursday, April 30, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.
During the quarter Longleaf Partners Global Fund had no new purchases and exited four holdings: Bio-Rad, Louis Hachette, Louisiana-Pacific and Walt Disney. Glanbia's shares held up well in a difficult market environment, though the stock continues to trade at undemanding multiples relative to global food and beverage staples peers. Delivery Hero reported largely inline FY25 results with FCF delivery stronger than our and street expectations.
Bio-Rad Laboratories (NYSE: BIO - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Risk and Volatility Bio-Rad Laboratories has a beta
Valeritas (OTCMKTS:VLRXQ - Get Free Report) and Bio-Rad Laboratories (NYSE: BIO - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Earnings and Valuation This table compares Valeritas and Bio-Rad
Pre-Market Stock Futures: Futures are trading lower on Tuesday morning after investors returned from the three-day Easter weekend to find a stock market ready to rally after some promising news on the war in Iran and a sense, among some across the financial world, that the market had put in a new bottom. Ed Yardeni,... Here Are Tuesday's Top Wall Street Analyst Research Calls: Ameriprise Financial, Arista Networks, Arm Holdings, Lennar, Morgan Stanley, Rocket Lab, Tractor Supply, Wingstop, Wix.com and More
Allspring Global Investments Holdings LLC cut its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 4.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 129,211 shares of the medical research company's stock after selling 5,556 shares during the period.
HOLMDEL, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its fourth quarter (Q4'25) and year ended December 31, 2025 (2025) results. BIO-key will host an investor call today at 10:00am ET (details below).
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced fourth quarter and full year 2025 financial results and provided a business update.
BKYI: Identity and Biometric Authentication Cybersecurity Provider BIO-key to Host Year-End Investor Call Tues., Mar 31 at 10am ET. Dial-in: 1-877-418-5460
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company.
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal.
HOLMDEL, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions enabling phoneless, tokenless, passwordless, and phishing-resistant authentication, today announced a strategic partnership with TD SYNNEX Public Sector (DLT Solutions), a leading technology partner to the U.S. public sector, to bring BIO-key's comprehensive suite of security solutions to federal, state, and local government agencies.
